December 19, 2024 Bio/Pharma/CRO

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints Prasinezumab continues to be well tolerated and no new safety signals were observed Roche is further evaluating the data and will work together with health authorities to determine next steps Basel, 19 December 2024 – Roche (SIX: RO,... Read more

November 26, 2024 Bio/Pharma/CRO

Roche reports update on Phase III SKYSCRAPER-01 study results

Basel, 26 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC).  SKYSCRAPER-01 is a global phase III, randomised, double-blind study evaluating tiragolumab plus... Read more

October 31, 2024 Bio/Pharma/CRO PAI Top-10 Product Launch

New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer

ItovebiTM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone in the INAVO120 study1 The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR-positive, HER2-negative breast cancer with a PIK3CA mutation, one... Read more

October 2, 2024 Bio/Pharma/CRO Lab Top-10 Microscopy

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery Combining Dynamic Biosensors’ Innovative Technologies with Bruker’s High-Performance SPR Portfolio to Establish a Leading Biosensors Business MUNICH–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Dynamic Biosensors GmbH , a pioneering company known for its breakthroughs in biosensor development,... Read more

July 2, 2024 Bio/Pharma/CRO Lab Top-10 Life Science Tools Molecular Spectroscopy

Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin

The Avance® 1.2 GHz NMR system will enable advanced studies of biomolecular structures and function in structural biology, pharmacology, and cellular biology BERLIN–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second... Read more

April 8, 2024 Acad, Gov/Utilities Atomic Spectroscopy Bio/Pharma/CRO Environ, Ag./Food & Bev Lab Top-10 Molecular Spectroscopy

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies ASILOMAR, Calif.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as... Read more

February 5, 2024 Bio/Pharma/CRO Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 M&A, Partnerships PAI Top-10 Product Launch

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Danaher Launches Collaboration with Cincinnati Children’s Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development,... Read more

February 5, 2024 Bio/Pharma/CRO Lab Top-10 Liq. Handling & Robotics Microscopy

Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024

Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024 Enables the Simultaneous Measurement of 64 Molecular Interactions BOSTON–(BUSINESS WIRE)– At the SLAS2024 International Conference and Exhibition, Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument. The SPR #64 system... Read more

January 4, 2024 Bio/Pharma/CRO Lab Top-10 Liq. Handling & Robotics Microscopy

Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio

Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio MISSISSAUGA, Ontario–(BUSINESS WIRE)– Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of... Read more

December 19, 2023 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure Interim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction 17 million people in the U.S. have confirmed... Read more